Tag: SCS therapy
Nevro announces launch of “only AI-driven technology in spinal cord stimulation”
Nevro Corporation has announced the US Food and Drug Administration (FDA) approval and limited market release of HFX iQ with HFX AdaptivAI—a responsive, personalised...
Saluda announces presentation of two chronic pain biomarker-based analyses at ASPN...
Saluda Medical has announced the recent presentation of two abstracts analysing biomarker-based spinal cord stimulation (SCS) data at the 2024 American Society of Pain...
Carryover effect exists and has “remarkably high” variability in spinal cord...
An international, multicentre study has confirmed the existence of the carryover or ‘echo’ effect—an interval before patients perceive the return of pain after their...
Boston Scientific announces positive WaveWriter SCS findings from SOLIS trial
Boston Scientific Corporation has announced positive one-year results from the SOLIS randomised controlled trial, demonstrating sustained pain relief using its WaveWriter Alpha spinal cord...
Saluda announces plans to present new EVOKE study data at NANS...
Saluda Medical has announced that its data will be presented at the upcoming North American Neuromodulation Society (NANS) annual meeting (18–21 January, Las Vegas,...
Washington state “poised” to extend spinal cord stimulation coverage following straw...
As per a recent statement from the North American Neuromodulation Society (NANS), the US state of Washington may be about to extend its insurance...
Nevro announces “profound improvements” in non-surgical refractory back pain patients treated...
Nevro Corporation has announced the publication of new 24-month data from the SENZA-NSRBP multicentre randomised controlled trial (RCT) in the Journal of Neurosurgery: Spine. The...
Boston receives expanded US FDA approval of SCS therapy for painful...
Boston Scientific has announced that the US Food and Drug Administration (FDA) has approved an expanded indication of the WaveWriter Alpha spinal cord stimulator...
Biotronik announces new data supporting effectiveness of RESONANCE multiphase stimulation paradigm
Biotronik Neuro has announced that results from the BENEFIT-02 trial—the “first of its kind” to clinically evaluate a multiphase stimulation paradigm—support the effectiveness of...
Two-year data indicate long-term effectiveness of Nevro’s SCS therapy in painful...
Nevro Corporation recently announced the publication of 24-month data from the SENZA painful diabetic neuropathy (PDN) randomised controlled trial (RCT)—the largest RCT to evaluate...
Medtronic receives CE-mark approval for Inceptiv closed-loop SCS to treat chronic...
Medtronic has received CE-mark approval for its Inceptiv closed-loop rechargeable spinal cord stimulator in the treatment of chronic pain.
Inceptiv is the first Medtronic spinal...
Health economic data show cost-dominance of Saluda’s EVOKE system over open-loop...
Saluda Medical has announced the publication of new health economic data in the Clinical Journal of Pain that provides “the strongest ever economic case” for the...
Cochrane Library urged to retract and revise recent SCS review over...
Pain physicians have urged the Cochrane Library to retract and revise a recent review of spinal cord stimulation (SCS) in the treatment of low...
Brain-computer interface plus SCS therapy enables thought-controlled walking after spinal cord...
Onward Medical has announced a recent publication in Nature showing that a wireless brain-computer interface (BCI) can use patients’ thoughts to modulate ARC therapy....
Abbott gains US FDA nod to treat non-surgical back pain with...
Abbott has announced that the US Food and Drug Administration (FDA) has approved its spinal cord stimulation (SCS) devices for the treatment of chronic...
The new standard for SCS therapy—neural activation measurement, targeting and maintenance
Jason Pope (Santa Rosa, USA) discusses closed-loop spinal cord stimulation (SCS) and its potential to provide sustained, holistic outcomes for chronic pain patients. In...
Review concludes SCS benefits do not outweigh associated risks and costs...
A recently published Cochrane review has concluded that the clinical benefits of spinal cord stimulation (SCS) do not outweigh the risks and costs associated...
Spinal cord stimulation found to “instantly improve” post-stroke arm and hand...
Spinal cord stimulation (SCS) therapy has been shown to trigger instant improvements in arm and hand mobility, enabling people affected by moderate-to-severe stroke to...
High-frequency spinal cord stimulation may be associated with “significant decrease” in...
High-frequency spinal cord stimulation (HF-SCS) for treating chronic refractory low back pain (CRLBP) may be associated with a significant decrease in total healthcare costs,...
Saluda Medical announces presentation of 36-month EVOKE trial data at NANS...
Saluda Medical has announced that late-breaking data from the "landmark" EVOKE clinical trial was presented at the recent North American Neuromodulation Society (NANS) annual...
Nalu Medical announces publication of two spinal cord stimulation clinical studies
Nalu Medical—a company working on miniaturised neurostimulation implants for the management of chronic intractable pain via both spinal cord stimulation (SCS) and peripheral nerve...
Abbott launches “world’s smallest” implantable, rechargeable SCS system for chronic pain
Abbott has announced the US Food and Drug Administration (FDA) approval of the company's Eterna spinal cord stimulation (SCS) system, which it claims is...
Spinal cord stimulation and other modalities will benefit from greater understanding...
Despite their clear significance in pain management, gender differences relating to the ways patients respond to neuromodulation therapies are relatively poorly understood and underpinned...
Onward reports positive study results in restoring arm and hand function...
Onward Medical recently announced that the Up-LIFT pivotal study evaluating its non-invasive spinal cord stimulation (SCS) ARC-EX therapy achieved its primary effectiveness endpoint of...
Recommended use of SCS in neuropathic pain has not led to...
Only a small proportion of neuropathic pain patients in England who are potentially eligible for spinal cord stimulation (SCS) have received this intervention over...
Abbott upgrades NeuroSphere myPath app for patient monitoring in neuromodulation trials
Abbott today announced that it has launched an upgraded version of its NeuroSphere myPath digital health app with enhanced functionality intended to help doctors...
